{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".000","upperLimit":"60.025","value":"25.490"},{"groupId":"OG001","lowerLimit":"1.493","upperLimit":"36.067","value":"18.780"},{"groupId":"OG002","lowerLimit":".000","upperLimit":"23.889","value":"11.610"},{"groupId":"OG003","lowerLimit":".000","upperLimit":"86.811","value":"32.340"},{"groupId":"OG004","lowerLimit":"8.660","upperLimit":"28.780","value":"18.720"},{"comment":"The median overall survival was not reached in the follow-up time period.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"17"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Dose Level 0: Carfilzomib IV (20 mg/m2) D1\\&D2 of C1 and carfilzomib IV (27 mg/m2)D8, D9, D15, D16 of C1. Carfilzomib IV (27 mg/m2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (27 mg/m2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m2)D8 C1-6.","id":"OG000","title":"Phase I - Part 1 Dose Level 0 (Carfilzomib 20/27 mg/m^2)"},{"description":"Dose Level 1: Carfilzomib IV (20 mg/m2) D1\\&D2 of C1 and carfilzomib IV (36 mg/m2)D8, D9, D15, D16 of C1. Carfilzomib IV (36 mg/m2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (36 mg/m2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m2)D8 C1-6.","id":"OG001","title":"Phase I - Part 1 Dose Level 1 (Carfilzomib 20/36 mg/m^2)"},{"description":"Dose Level 2: Carfilzomib IV (20 mg/m2) D1\\&D2 of C1 and carfilzomib IV (45 mg/m2)D8, D9, D15, D16 of C1. Carfilzomib IV (45 mg/m2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (45 mg/m2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m2)D8 C1-6.","id":"OG002","title":"Phase I - Part 1 Dose Level 2 (Carfilzomib 20/45 mg/m^2)"},{"description":"Dose Level 3: Carfilzomib IV (20 mg/m2) D1\\&D2 of C1 and carfilzomib IV (56 mg/m2)D8, D9, D15, D16 of C1. Carfilzomib IV (56 mg/m2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (56 mg/m2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m2)D8 C1-6.","id":"OG003","title":"Phase I - Part 1 Dose Level 3 (Carfilzomib 20/56 mg/^2)"},{"description":"Cohort 0: Carfilzomib IV (56 mg/\\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.","id":"OG004","title":"Phase I-Part 2 Cohort 0 (Carfilzomib 56 mg/m^2+Dexamethasone)"},{"description":"Carfilzomib IV (56 mg/\\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.","id":"OG005","title":"Phase 2 (Carfilzomib 56 mg/m^2+ Dexamethasone)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Completion of follow-up (median of 23.3 months)","title":"Median Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}